• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

63.44 -1.94 (-2.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) Presents a Compelling GARP Opportunity ↗
June 24, 2026
Via Chartmill
News headline image
Kiniksa (KNSA) Q1 2026 Earnings Transcript ↗
June 01, 2026
Kiniksa (KNSA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Screens as Affordable Growth ↗
May 29, 2026
Via Chartmill
Kiniksa Pharmaceuticals (KNSA) Shows Explosive Potential with Perfect Minervini Trend Template and 460% EPS Growth ↗
May 25, 2026
Via Chartmill
News headline image
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally ↗
May 23, 2026
Kiniksa Pharmaceuticals is gaining momentum after strong ARCALYST sales growth, raised revenue guidance, and optimism surrounding its next-generation pipeline 
Via MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surges on Q1 Earnings Beat and Raised ARCALYST Guidance ↗
April 28, 2026
Via Chartmill
Topics Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surfaces as a GARP Opportunity with a Growth Rating of 8 ↗
April 25, 2026
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the Minervini Trend Template with High-Growth Momentum ↗
April 03, 2026
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a Compelling Growth and Technical Setup ↗
March 30, 2026
Via Chartmill
News headline image
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today ↗
April 28, 2026
The biotech delivered a beat-and-raise first quarter. 
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
April 28, 2026
Via Chartmill
News headline image
What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge ↗
April 17, 2026
This biotech innovator in inflammatory disease therapies reported a notable insider sale amid strong revenue growth and recent stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kiniksa Pharmaceuticals (KNSA) Shows High Growth Momentum and Technical Breakout Potential ↗
April 14, 2026
Kiniksa Pharmaceuticals (KNSA) exemplifies a high-growth momentum stock with strong fundamentals and a positive technical setup for potential breakout. 
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup ↗
March 23, 2026
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment ↗
March 20, 2026
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup ↗
March 05, 2026
Via Chartmill
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup ↗
March 02, 2026
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing ↗
February 27, 2026
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment ↗
February 25, 2026
Via Chartmill
News headline image
Kiniksa (KNSA) Q4 2025 Earnings Call Transcript ↗
February 24, 2026
Kiniksa (KNSA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines Strong Growth with Bullish Technical Setup ↗
February 10, 2026
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with Strong Technical Setup ↗
January 29, 2026
Via Chartmill
News headline image
Earnings Scheduled For October 28, 2025 ↗
October 28, 2025
 
Via Benzinga
News headline image
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the High-Growth Momentum and Trend Template Strategy ↗
December 13, 2025
KNSA stock meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including surging EPS and revenue. 
Via Chartmill
News headline image
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript ↗
November 27, 2025
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Combines Technical Strength and Fundamental Growth Momentum ↗
November 20, 2025
KNSA stock shows strong technical momentum per the Minervini Trend Template and impressive fundamental growth with 421% EPS growth. 
Via Chartmill
News headline image
What to Expect from Kiniksa Pharmaceuticals's Earnings ↗
October 27, 2025
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Kiniksa Pharmaceuticals ↗
October 17, 2025
 
Via Benzinga
News headline image
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen ↗
October 08, 2025
Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance. 
Via Chartmill
News headline image
What Analysts Are Saying About Kiniksa Pharmaceuticals Stock ↗
September 29, 2025
4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a diverse set of opinions from bullish to bearish. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap